Physician profile
Andy P Stephens
NPI 1568450278
$3,182.70
in general payments reported to CMS, 2019-2025
21 companies · $70.70 in 2025
The $70.70 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $575 · 2021: $534 · 2022: $581 · 2023: $371 · 2024: $798 · 2025: $70.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,239.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $469.78 | 2019-2022 | |
| Alcon Vision LLC | $374.35 | 2019-2024 | Total30 |
| Biotissue Holdings INC. | $369.62 | 2022-2024 | |
| Genentech USA, INC. | $273.16 | 2020-2023 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $232.67 | 2023-2024 | Syfovre |
| Novartis Pharmaceuticals Corporation | $147.94 | 2020-2022 | |
| Sight Sciences, INC. | $138.73 | 2022 | |
| Bausch & Lomb Americas INC. | $134.21 | 2024 | Infuse |
| Dompe US, INC. | $122.00 | 2024 | Oxervate |
| Glaukos Corporation | $119.88 | 2024 | Idose |
| Ocular Therapeutix, INC. | $119.68 | 2020 | |
| Kala Pharmaceuticals, INC. | $117.24 | 2021 | |
| Abbvie INC. | $106.15 | 2022-2025 | Alphagan P, Vuity, Lumigan |
| Abb Con-Cise Optical Group LLC | $102.43 | 2021 | |
| Aerie Pharmaceuticals, INC. | $86.71 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $86.71 | 2020 | |
| Sun Pharmaceutical Industries INC. | $85.18 | 2020-2023 | Cequa |
| Coopervision INC. | $34.58 | 2022-2023 | Myday Contact Lens |
| Quidel Corporation | $27.65 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $21.78 | 2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andy Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.